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Programmable nucleases based on the FokI nuclease domain have been used 
widely for genome targeting in various cells and organisms. Recent 




CRISPR/Cas system has the prospect of being another programmable 
nuclease for genome targeting in other higher eukaryotes. 
In this study, I have used a CRISPR/Cas system as a programmable RNA-
guided endonucleases (RGENs), which cleave DNA in a targeted manner for 
genome engineering in human cells. These enzymes can induce site specific 
double strand breaks (DSBs) in chromosomal DNA and the repair of DSBs 
gives rise to targeted genome modifications via non-homologous end joining 
or homologous recombination. In this study, RGENs can induce efficient 
mutations at frequencies of up to 75% in human K562 cells. Compared to 
ZFNs or TALENs, the specificity of RGENs can easily be customized by 
synthesizing new guide-RNA molecules.  
Furthermore, I investigated off-target effects of RGENs. Off-target 
cleavage at unwanted loci can cause genetic instability including 
tumorigenesis or chromosome structural variations. The present study 
demonstrates that RGENs can efficiently discriminate on-target sites from off-
target sites that differ by two bases. Indeed, exome sequencing analysis shows 
that RGEN-induced mutant clone without off-target mutations can be isolated. 
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I. Introduction  
 
 
Genome manipulation is an essential technique for studying genome and 
diseases. Although gene targeting by spontaneous homologous recombination  
(HR) has been used to alter genome sequence for several decades (CAPECCHI 
1989), it is a time- and effort-consuming process due to its low efficiency 
(SEDIVY and SHARP 1989). There are different methods for manipulating 
genome with specific enzyme such as integrase (MILLER and ROSMAN 1989) 
or transposase (GEURTS et al. 2003; RUBIN and SPRADLING 1982); however, 
it is based on random integration (SCHRODER et al. 2002; WU et al. 2003) 
which can cause cancer or other defects (HACEIN-BEY-ABINA et al. 2003). 
Genome targeting efficiency could be greatly enhanced by the DSB repair 
process (ROUET et al. 1994). It is well known that the yeast homing 
endonuclease, I-SceI, can promote HR with high efficiency (>1,000 fold) at 
targeting locus (JASIN 1996); however, there is no endogenous target 
sequence of rare-cutting restriction enzymes in human or other higher species. 
The first programmable restriction enzyme, zinc finger nuclease (ZFN), 
consists of the zinc finger domain which is well-characterized. It is one of the 
most common DNA binding motifs and the non-specific DNA cleavage 




specificity of ZFN is determined by its zinc finger composition and it can be 
customized by fusing three to six fingers (KIM and PABO 1998) of several 
hundreds of naturally occurring (BAE et al. 2003) or engineered zinc finger 
domains (REBAR and PABO 1994).  
Carroll showed ZFN could induce a DSB at the desired locus to manipulate 
the genome of Drosophila melanogaster with highly enhanced efficiency 
(BIBIKOVA et al. 2003). As a result of this milestone study, ZFN have been 
used to induce site-specific DSBs to modify the genomes in a targeted manner 
in cells (HOCKEMEYER et al. 2009; KIM et al. 2009; URNOV et al. 2005) and 
organisms (CUI et al. 2011; DOYON et al. 2008; GEURTS et al. 2009; MENG et 
al. 2008; MORTON et al. 2006; SHUKLA et al. 2009; TOWNSEND et al. 2009; 
YANG et al. 2011; YU et al. 2011).  
However, broad applications of ZFNs were hampered by the lack of a 
convenient and rapid method for the design of functional ZFNs (MAEDER et 
al. 2008). Indeed, some of the ZFNs induced cytotoxicity by off-target 
cleavage (URNOV et al. 2010). Transcription activator like effecter nucleases 
(TALENs) showed improved efficiency and specificity than ZFN (KIM et al. 
2013; MILLER et al. 2011); however, a variety of materials and sub-cloning 
steps were needed to synthesize TALENs (REYON et al. 2012; SANJANA et al. 
2012).  
The clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated protein (Cas) system has a role for adaptive 




2012). The ribonucleoprotein (RNP) complex of type II CRISPR/Cas system 
in Streptococcus pyogenes wihch consists of CRISPR RNA (crRNA), trans-
activating RNA (tracrRNA) and Cas9 protein, performs as a sequence-specific 
endonuclease that cleaves foreign genetic material to protect the host cells. In 
S.pyogenes, pre-crRNAs are transcribed at CRISPR locus containing spacers 
and direct repeat sequences, and are further processed into mature crRNAs by 
RNase III (DELTCHEVA et al. 2011). Recent papers have shown that the 
crRNA did function as a guide-RNA whose specificity is determined by 
spacer sequences (JINEK et al. 2012). Indeed, the specificity of crRNA is 
programmable by replacing the 20 base sequences of 5’ upstream of them. 
The specificity of an RGEN is determined by the 20 base pair sequences in 
crRNA and the NGG trinucleotide, known as the protospacer adjacent motif 
(PAM) (MOJICA et al. 2009), recognized by Cas9 itself. The 22 base pairs of 
specificity might be sufficient to ensure the specific genome targeting in 
higher eukaryotes. 
Here, I present the evidence that RGENs can induce site-specific genome 
modifications in human cells at high frequencies (CHO et al. 2013a). RGEN 
did not induce severe cytotoxicity and significant off-target effects (CHO et al. 
2013b). These results propose that RGEN can be a versatile and a convenient 





II. Materials and Methods 
 
 
1. Construction of Cas9 expression plasmid 
The Cas9 coding sequence (4,104 bp), derived from Streptococcus pyogenes 
strain M1 GAS (NC_002737.1), was reconstituted using the human codon 
usage table. Humanized Cas9 sequence was converted to oligonucleotide to 
synthesis (ROUILLARD et al. 2004). First, 1-kbp DNA segments were 
assembled using overlapping 35-mer oligonucleotides and Phusion 
polymerase (New England Biolabs), and cloned in to T-vector (Solgent). A 
full length Cas9 sequence was assembled using four 1-kbp DNA segments by 
overlap PCR and sequenced by Sanger sequencing (Figure 1).  
  The Cas9 open-reading frame was subcloned into p3s, which was derived 
from pcDNA3.1 (Invitrogen). In this vector, Cas9 protein is expressed under 
the control of the CMV promoter. To ensure protein expression and 
compartmentalization, HA-epitope and a nuclear localization signal (NLS) 










Figure 1. Schematic representation for construction of the Cas9-encoding 






































Figure 2. Amino-acid sequence of the expressed version of Cas9 used in this 
study. The amino-acid sequence of the Cas9 protein encoded in our Cas9 
expression plasmid is presented. The sequence of the NLS (PPKKKRKV) and 






2. Construction of guide-RNA transcription plasmid 
Human U6 promoter was used to drive expression of RNA components of 
CRISPR/Cas9 system because of its defined transcription start and 
termination site (LOBO et al. 1990). U6 promoter was sub-cloned from 
pLKO.1-puro plasmid into pUC18 using AatII/EcoRI restriction sites. For 
convenient replacement of target sequence, type IIs restriction sites were 




















Figure 3. DNA construct for crRNA transcription under hU6 promoter. BsaI 
type IIs restriction enzyme sites (Red) were employed to generate sequence-
independent overhang. The 3’ end of hU6 promoter and backbone sequence of 
crRNA are shown in green and blue, respectively. The arrow indicates the 











3. Cas9 protein purification 
The Cas9 expression cassette was sub-cloned into pET28-b(+) and 
transformed into BL21(DE3) strain. The expression of Cas9 was induced 
using 0.2 mM IPTG for 16 hr at 18℃. The Cas9 protein containing the His6-
tag was purified using Ni-NTA agarose beads (Qiagen) and diazyed against 
20 mM HEPES pH 7.5, 150 mM KCl, 1 mM DTT, and 10% glycerol (JINEK 
et al. 2012). The Purified Cas9 protein was concentrated using Ultracel 100K 
cellulose column (Millipore). The purity and concentration of Cas9 were 
analyzed by electrophoresis using 8% SDS-PAGE gel. 
 
4. Preparation of guide-RNA 
RNA was in vitro transcribed through run-off reaction by T7 polymerase 
using MEGAshortscript T7 kit (Ambion) according to the manufacturer’s 
manual. Templates for RNA in vitro transcription were generated by 
annealing two complementary oligonucleotides. To synthesize large amount 
of guide-RNA, 200 nM of template DNAs were incubated with 10 U/μl of T7 
RNA polymerase, 0.4 U/ μl of yeast inorganic pyrophophatase, 4 mM of each 
NTP and 10 U/μl of RNase inhibitor in a reaction buffer including 40 mM 
Tris-HCl pH 7.9, 20 mM MgCl2, 2mM spermidine and 10 mM DTT. RNA 
was purified and recovered in nuclease-free water followed by 




Purified RNA was quantified by spectrometry and analyzed by 
electrophoresis using 8 % denaturing urea-PAGE gel. 
 
5. In vitro cleavage assay 
170-1,700 ng of purified Cas9 protein was incubated with 350 ng of plasmid 
DNA or 200 ng of PCR amplicon with 50-500 ng of RNAs in a reaction 
volume of 20 μl in NEB buffer 3 for 1 hrs at 37℃. Digested DNA was 
visualized and analyzed by electrophoresis with agarose gels. 
 
6. Cell culture and transfection 
K562 (ATCC, CCL-243) cells were grown in RPMI-1640 with 10% FBS and 
a penicillin/streptomycin mix (100 U/ml and 100 μg/ml, respectively). 2×10
6
 
K562 cells were transfected with 20 μg of Cas9-encoding plasmid using the 
4D-Nucleofactor, SF Cell Line 4D-Nucleofactor X kit, and Program FF-120 
(Lonza) according to the manufacturer’s instruments. After 24 hrs, 60 μg of 
crRNA and 120 μg of tracrRNA were transfected into 1×10
6
 K562 cells.  
HEK293/17 cells (ATCC, CRL-11268) or HeLa cells (ATCC, CCL-2) 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin, 0.1 mM 
nonessential amino acids, and 10% FBS. 0.8×10
5
 HeLa cells were transfected 
with 500 ng of Cas9-encoding plasmid and 500 ng of tracrRNA/crRNA 




manufacturer’s protocol. Cells were collected 2-9 days after transfection and 
genomic DNA was isolated. 
   
7. Preparation of nuclear extract and western blotting 
2×10
6
 K562 cells transfected with Cas9-encoding plasmids were harvested 
after 48 hrs transfection. 50 ul of Buffer A (10 mM HEPES-KOH pH 7.9, 
10mM KCl, 0.1mM EDTA, 1mM DTT, 0.4% IGEPAL, and protease inhibitor 
cocktail) was added to cell pellet. After disrupting cell pellet by pipetting, the 
mixture was adapted to centrifugation at 16,000 g for 3 min. The supernatant 
was saved as a cytosolic fraction. The residual pellet was washed with Buffer 
A twice, then 50 ul of Buffer B (20mM HEPES-NaOH pH 7.9, 400 mM NaCl, 
1mM EDTA, 10% glycelol, 1mM DTT and protease inhibitor cocktail) was 
added to pellet. The re-suspended pellet was incubated for 2 hrs at 4 ℃. After 
centrifugation, supernatant was saved as a nucleus fraction. The concentration 
of each fraction was measured by Bradford assay. Proteins were resolved on 8% 
SDS-PAGE gel and adapted to western blotting. All antibodies used in 
western blotting were purchased from Santa Cruz. 
 
8. Validation of mutations 
Purified genomic DNAs from RGEN-treated human cells were adapted to 
analysis for RGEN-induced mutagenesis. The region including the targets or 




polymerase. The amplicons were denatured and re-annealing to from 
heteroduplex using thermocycler and a following program (95℃ for 2 min, -
2℃/s to 85℃, -0.1℃/s to 25℃). 10 μl of re-annealed DNA was incubated 
with 5U of T7E1 mismatch specific enzyme and NEB buffer 2 in a reaction 
volume of 20ul for 20 min at 37℃, and then analyzed by electrophoresis 
using 1.5% agarose gels. The mutation frequency was calculated based on the 




HeLa cells transfected with the C4BPB-specific RGEN were fixed on glass 
slides and incubated first with anti-TP53BP1 rabbit polyclonal antiboby 
(Bethyl Laboratories) and then with Alexa Fluor 488-conjugated secondary 
antibody (Invitrogen). Cells were mounted in the presence of DAPI (sigma) 
and examined under a fluorescence microscope (Zeiss). 
 
10. Targeted deep sequencing and analysis 
Genomic regions harboring on-target and potential off-target sites of RGENs 
were amplified using Phusion polymerase and subjected to paired-end read 
sequencing using Illumina MiSeq at Bio Medical Laboraories. Insertion or 
deletion located around the RGEN cleavage site was considered as a signature 




11. Exome sequencing and analysis 
Genomic DNAs from RGEN-induced mutant clones were used to construct 
exome-captured libraries using a TrueSeq Exome Enrichment kit (Illumina). 
PCR enriched libraries were subjected to Illumina HiSeq 2000 at Bio Medical 
Laboratories. Raw Reads in FASTQ format were aligned to the 
NCBI36/Hg18 reference genome using BWA-0.5.9. PCR duplicates were 
removed using SAMtools-0.1.16. Single nucleotide variants and indels were 
called using GATK-1.4. Since engineered nucleases rarely induce substitution 
via DSB repair process (KIM et al. 2009), only indel variants were considered 
in further analysis as previously described. Shared variants found in at least 
two non-relative clones were excluded. Further, naturally-occurring common 
indels were also excluded by comparing to dbSNP build 130. Indel variants 
presented in wild-type K562 cells were not considered as RGEN-induced 
mutations.  
 Remained indel variants were analyzed by two methods. First, Amplicons 
harboring the indel were subjected to in vitro cleavage assay. Second, 
sequences around indel junction were compared to the on-target sequences to 








Table 1. Primer sequences used in T7E1 assay. 
 




































Table 2. Oligonucleotide sequences used in vitro transcription. 
 
For short chimeric guide-RNA transcription 
Direction Sequence (5' to 3') 
F 





[Target complementary sequence 20 mer] CCTATAGTGAGTCGTA 
TTAATTTC 
 
For crRNA transcription 
Direction Sequence (5' to 3') 
F 
GAAATTAATACGACTCACTATAGG [Target sequence 20 mer] 
GTTTTAGAGCTATGCTGTTTTG 
R 
CAAAACAGCATAGCTCTAAAAC [Target complementary 
sequence 20 mer] CCTATAGTGAGTCGTATTAATTTC 
 
For tracrRNA transcription 














Table 3. Primer sequences used in Sanger sequencing. 
 
















1. Establishment of RGENs for genome targeting 
 
a. In vitro cleavage assay 
In prokaryotes, crRNA (42 mer) and tracrRNA (75 mer) are generated from 
the host genome (Figure 4) (DELTCHEVA et al. 2011). A single-chain chimeric 
RNA (62 mer) produced by fusing an essential portion of crRNA and 
tracrRNA can replace the two RNAs in the Cas9/RNA complex to form a 
functional endonuclease (JINEK et al. 2012). In order to test the DNA 
cleavage activity of Cas9 in human cells, the target sequence was selected in 
human CCR5 gene, which encodes an essential receptor of HIV and is a target 










A Cas9 target sequence consists of a 20 bp DNA sequence complementary to 
the crRNA and the trinucleotide (5’-NGG-3’) PAM recognized by Cas9 itself. 
Purified recombinant Cas9 was incubated with an in vitro transcribed 
chimeric-RNA and a plasmid harboring the 23 bp target sequence. Cas9 
efficiently cleaved the plasmid at the expected position only in the presence of 


















Figure 5. In vitro cleavage of plasmid DNA by Cas9. An intact circular 






b. RGEN-mediated mutagenesis in human cells 
For efficient cleavage of chromosomal DNA, Cas9 has to be 
compartmentalized to nuclear. To demonstrate this, protein extract of each 
fraction of cell was isolated and subjected to western blotting. As expected, 
the presence of Cas9 in both nuclear and cytosol was confirmed by anti-HA-







Figure 6. Expression and compartmentalization of the Cas9 protein in human 
cells. Protein expression in each fraction of K562 cells was determined by 
western blot. Antibodies against HA-epitope, TNFR, PARP1, or GAPDH 
were used as makers for Cas9, cytosol extract (CYT), nuclear extract (NUC), 





To test whether RGENs could be used for targeted disruption of 
endogenous genes in human cells, human K562 cells were transfected with 
Cas9-encoding plasmid and a synthetic chimeric-RNA targeting CCR5. 
Genomic DNA was isolated from transfected cells and subjected to T7E1 
assay. Cleaved bands, indicate that the induced mutations, were found only 
when the cells were co-transfected with both Cas9 and RNA (Figure 7). 
Mutation frequencies, estimated from the relative DNA band intensities, were 
RNA-dosage dependent. DNA sequencing analysis of PCR amplicons 
corroborated the induction of RGEN-mediated mutations at the targeted site.  
Next, CCR5 targeting guide-RNA was replaced with a newly synthesized 
guide-RNA designed to target the human C4BPB, which encodes the beta 
chain of C4b-binding protein, a transcription factor. As shown in CCR5, this 
RGEN induced mutations at the chromosomal target site in K562 cells. 
Sequencing analysis of PCR amplicons revealed that, out of four mutant 
sequences, one clone contained a single-base insertion, and one a two-base 
insertion precisely at the expected cleavage site. These results indicate that 
RGENs can cleave chromosomal DNA at the expected position as well as in 














Figure 7. RGEN-driven mutations at endogenous chromosomal sites. (A) 
CCR5 and (B) C4BPB locus. The mean frequencies and standard error of the 
mean of independent experiments are shown. The regions of the target 
sequence complementary to the guide-RNA and the PAM sequence are shown 
in red and blue, respectively. The red triangle indicates expected cleavage site. 




c. Guide-RNA structure 
In order to investigate if RGEN could be generally used to target human 
genome, an additional 18 genes of human genome were targeted. However, 
there were no RGENs that could induce targeted mutations up to the detection 
limits (~1%). I speculated that the single-chain chimeric guide-RNAs were 
active as well as natural forms (dual guide-RNA) of crRNA and tracrRNA in 
vitro (Figure 8). However, RNA structure or stability may be affected by the 





















Figure 8. Schematic diagram of short chimeric guide-RNA and dual guide-
RNA. Sequences derived from crRNA and tracrRNA were shown in green 






To compare the activity of chimeric RNAs and dual guide-RNAs, three in 
vitro transcribed crRNAs and tracrRNAs or chimeric RNAs were employed in 
an in vitro assay (Figure 9). One of the CCR5 targeting RGEN showed no 
difference at cleavage efficiency. Another RGENs showed enhanced or 
reduced efficiency when the natural forms of RNAs were used.  
To test whether different RNA structures affect DNA targeting efficiency in 
cells, four RGENs were introduced into K562 cells. When the chimeric RNAs 
were tested, only one out of three targets showed mutations. Interestingly, 
dual guide-RNAs showed drastically enhanced efficiencies at all target 
sequences examined (Figure 9). These results suggest that essential regions 





















Figure 9. Comparison of short chimeric guide-RNA and dual guide-RNA. (A) 
Two types of guide-RNA against the three target sequences in CCR5 were 
compared in vitro (Upper) and in cellular (Bottom). (B) Identification of 
mutatation sequences induced by crRNA/tracrRNA/Cas9 complex. Each 





2. Analysis of off-target effects of RGENs 
 
a. Analysis of RGEN-induced cytotoxicity 
Non-specific engineered nucleases showed several numbers of foci against 
DSB repair regulator by immunostaining (MILLER et al. 2007). In order to test 
the specificity of RGEN, the number of DSBs in an RGEN-transfected cell 
was analyzed using anti-TP53BP1, a regulator of DSB repair response 
(O'DRISCOLL and JEGGO 2006). In contrast to positive control, RGEN-treated 
cells showed only ~1 DSB per cells (Figure 10). Thus, RGEN did not induce 







Figure 10. RGEN-induced DSBs in cells detected by TP53BP1 staining. 
HeLa cells transfected with the C4BPB-specific RGEN were fixed and 
adapted to immunostaining by anti-TP53BP1 antibody. DAPI (blue) and 
TP53BP1 (green) images were merged. Etoposide (1 uM) was used as a 
positive control. The average number of foci per cell and the standard error of 




If engineered nucleases induce non-specific DSBs in a cell, it causes 
cytotoxic effect which give rises to cell death (PRUETT-MILLER et al. 2008). 
Thus, mutations become reduced with the passage of time. To investigate 
whether RGEN could induce a cytotoxic effect in a cell, mutation 
frequencies were measured with the course of time. Mutations induced by 
RGEN were stably maintained, even at 8 days post-transfection (Figure 11). 








Figure 11. Stable maintenance of RGEN-induced mutant cells. Mutation 






b. Analysis of RGEN specificity using mismatched guide-RNA 
Although RGEN showed no obvious cytotoxicity, recent studies showed that 
Cas9 complexed with a guide-RNA that contains a one-base mismatch to the 
target sequence can cleave the target DNA both in human (CONG et al. 2013), 
and in bacterial cells (JIANG et al. 2013), and in vitro (JINEK et al. 2012). 
RGENs tolerate mismatches especially in the 5’ upstream region, but not in 
the seed region of 6- to 11- nucleotides that is immediately upstream of the 
PAM sequence. In order to test whether CCR5 targeting RGEN tolerate the 
mismatches, crRNAs with one to three mismatches were synthesized and 
introduced into K562 cells (Figure 12A).  
It was observed that mismatches in 8 bp of 5’ upstream were tolerable 
(Figure 12B). This was consistent with the results of previous reports. 
However, when one additional mismatch was introduced within 11 bp 
upstream of the PAM, RGEN mediated mutation frequencies was lower than 
the limit of detection. Surprisingly, three mismatches were not tolerable, even 












Figure 12. Specificity of RGEN using mismatched guide-RNA. (A) Sequence 
of endogenous CCR5 target (Top) and the mismatched crRNA variants 
(Bottom). (B) T7E1 assay for K562 cells transfected with Cas9 plasmid and 




c. Analysis of off-target effects of RGENs at homologous sites 
The experiments using mismatched guide-RNAs were convenient for 
exploring the specificity of RGEN, however, it has a critical limitation that the 
mismatched RNAs were not verified for activities against to their on-target 
sequences. Thus, to investigate the specificity of RGEN, mismatched target 
sequences have to be examined using identical guide-RNAs. To this end, the 
most homologous sequences to target sequences of CCR5 were searched for 
in the human genome (Figure 13A). T7E1 assays showed that mutations were 
not induced at these sites (Figure 13B): three sites with two mismatches each, 











Figure 13. Undetectable off-target mutations at homologous sites of CCR5 
targeting RGEN. (A) Homologous sequence of CCR5 on-target sequence. 
Mismatched sequences were shown in red and the PAM sequences were 





To examine the off-target effect of RGEN more systematically, potential 
off-target sequences were searched with the following categories: 1) sites with 
conserved sequences in seed region; or 2) sites with one to three mismatches 
in the entire 22 bases. Due to poor sensitivity of T7E1 assay, further analysis 
was addressed by targeted deep sequencing. The two RGENs induced indels 
at frequencies of 75% and 60% at corresponding on-target sites of C4BPB and 
CCR5 in K562 cells, respectively. In sharp contrast, no indels were detected at 
any measurable frequency at any of the putative off-target sites (Figure 14). 
CCR5 targeting RGEN did not induce any mutations at two sites (off15 and 
off16) that each contained a one-base mismatch in the 11-bp seed region and 
another one-base mismatch in the 5’ upstream region. Indeed no mutations 
were found even at Off1 sites of C4BPB, whose three mismatches are all 
located in the 5’ upstream region. Note that the off-17 site contained a single-
base mismatch in the 20-bp sequence corresponding to the crRNA and 
another single-base in the PAM. No indels were detected at this site, 




















Figure 14. Mutation frequencies at on-target and potential off-target sites of 
the CCR5- (A) and C4BPB- (B) specific RGENs in K562 cells. Cells were 
transfected with crRNA, tracrRNA, and the Cas9 plasmid or the Cas9 plasmid 
alone (negative control). PCR amplicons that span the on-target site and 
potential off-target sites were subjected to deep sequencing. Sequences that 








The off-target effects were also addressed by RGEN-encoding plasmids in 
another human cell line, HeLa, and it was found that these RGENs 
discriminated on-target sites from their most likely off-target sites by a factor 
of >10,000-fold (Figure 15). These results suggest that the 5’ upstream region 
outside the seed region in the target sequence also contributes to the 
specificity of RGEN, and that RGENs cannot efficiently clave chromosomal 
DNA with mismatches of two or more nucleotides, at least one of which 












Figure 15. Mutation frequencies at on-target and potential off-target sites of 





Next, the specificity of RGENs was addressed by in vitro cleavage assay 
(Figure 16). Cas9/crRNA/tracrRNA complex was incubated with plasmids 
that contained either the CCR5 on-target sequence or off-target sequences. 
Interestingly, the CCR5-specific RGEN showed a low level (<1%) of 
cleavage activity toward plasmids that contained the off-target sequences, 
suggesting that RGENs function less discriminatingly in vitro than they do in 
cells under this experimental conditions. To investigate how one- or two-base 
mismatches were different in manner of specificity of RGEN, it was generated 
that plasmids which contained artificial sequences with each single base 
mismatch (off15-1, 15-2, 16-1 and 16-2). These hybrid sequences were 
cleaved much more efficiently by the ribonucleoproein complex than were the 
off-target sequences with two-base mismatches (Off15 and off16). This result 
indicates that RGENs can distinguish on-target sites from off-target sites with 












Figure 16. In vitro cleavage assay of on-target or potential off-target 
sequences by the CCR5-specific RGEN. Plasmids that contain putative off-
target (A) or hybrid (B) sequences were digested with the recombinant Cas9 
protein complexed with crRNA and tracrRNA. (C) DNA sequences of the on-




d. Extended analysis of off-target effects of RGENs 
To address the generality of specificity of RGENs, target sequences which 
have another endogenous site with one or two mismatches were searched in 
human genome (Table 4). CCR5 was chosen for targeting because it has the 
most homologous gene, CCR2. An additional 9 RGENs were designed to 
target CCR5 differing by one- or two- base mismatches with CCR2. The 
mutation frequencies were measured at on-target in CCR5 and off-target in 
CCR2. Three RGENs (Figure 17A, B, and C) did not induce any off-target 
mutations at the CCR2 sites that carried two-base mismatches. One RGEN 
(Figure 17D) induced off-target mutations at the CCR2 site that carried a one-
base mismatch in the seed region and another one-base mismatch in the 
upstream region at a frequency of 1.8%, 29-fold lower that the on-target 
mutation frequency. 
However, RGENs cannot efficiently discriminate on-target sites from off-
target sites that differ by a single base. Two RGENs (Figure 17F and G) 
showed undistinguishable mutation frequencies at off-target compare to on-
target; two RGENs were still able to discriminate on-target sites from off-
target sites with a single base mismatch by a factor of 7.2- to 42-fold. Thus, 
all four RGENs (Figure 17E to H) induced indels at frequencies that ranged 
from 1.6% to 43% at off-target sites that carried a single-base mismatch either 
in the seed region or the upstream region. One RGEN (Figure 17I) had an off-




the on-target site from the off-target sites by 490-fold, again confirming the 






















Figure 17. Analysis of RGEN-induced mutations at on-target and off-target 
sites. (A) - (I) K562 cells were transfected with RGENs that target nine 





These RGENs did not induce any indels at several potential off-target sites 
identified in other loci (Figure 17). Taken together, these results suggest that 
RGENs can distinguish on-target sites from off-target sites that differ by at 
least two bases, and that one could avoid or minimize off-target effects of 
RGENs by choosing unique target sites that do not have homologous 




Table 4. Summary of potential off-target sites analyzed in this study. The number of in sillico-searched potential off-target 





















mis0 1(1) 1(1) 1(1) 1(1) 1(1) 1(1) 1(1) 1(1) 1(1) 1(1) 
mis1 (0) (0) (0) (0) (0) (0) 1(1) 1(1) 1(1) 1(1) 
mis2 (0) 2(2) 3(3) 1(1) 3(3) 4(6) (0) 1(1) 1(2) 1(1) 




e. Analysis of clonal exome sequencing 
To examine whether the off-target mutations were induced at any 
unpredictable sites in human genome, exome sequencing were performed to 
identify off-target mutations on a genomic scale. Using limiting dilution, 
clonal populations were obtained which have RGEN-induced mutations in 
CCR5 or C4BPB. Of 37 or 47 clones, 29 (78%) or 35 (74%) had mutations in 
the CCR5 or C4BPB, respectively. These high mutation frequencies were 
comparable to those observed with deep sequencing. Genomic DNA isolated 
from one C4BPB-disrupted clone, two CCR5-disrupted clones, and wild-type 
K562 cells was subjected to exome sequencing. Analysis of the exome 
sequence data revealed a total of 308 indels present in the four clones, 
including wild-type cells, compared to the reference genome; 255 in CCR5-
disrupted clone #1, 246 in CCR5 clone #2, 233 in the C4BPB clone, and 253 
in the wild-type clone (Figure 18) (Note that the numbers are comparable in 
these clones).  Among these, 190 indels were present in all 4 clones 
including wild-type cells and 74 indels were shared in at least 2 clones. These 
indels were excluded from further analysis. 10 indels were found only in the 
wild-type clone, which suggests that the coverage of exome sequencing was 
not 100%. Likewise, 8, 9, and 17 indels were found only in the C4BPB clone, 










Figure 18. Validation of indels found in exome sequencing. A Venn diagram 














The 13 indels reported in a public database (dbSNP build 130, NCBI) were 
excluded in further analysis (Table 5) (OUSTEROUT et al. 2013), because they 
are unlikely to result from RGEN-mediated DNA cleavages. Sanger and deep 
sequencing were used to show that most of these “clone-specific” indels are 
present even in wild-type cells. Then, putative off-target sequences around the 
remaining indels were searched in the reference genome (Table 7). Other than 
the on-target mutations induced by the RGENs in these clones, none of these 
indels were associated with potential off-target sites. It is most likely that the 
indels in gene-disrupted clones were the results of incomplete coverage of 
exome sequencing (Table 6) (CLARK et al. 2011). Exons are captured before 
sequencing but this process covers only <90% of the human exome. >10% of 















Table 5. Summary of exome sequencing results. Indels found in mutant 




 RsNumbers of common indels in dbSNP build 130 are listed. 
**
 Sanger sequencing or deep sequencing (MiSeq) showed that these indels were 
present in wild-type K562 cells. In vitro, PCR products spanning these indels were 




















3,242,297,629  52.1  91.6  
CCR5_#2 3,571,954,659  57.4  90.8  
C4BPB 2,288,223,860  36.8  89.7  




To rule out the possibility that the remaining sites are cleaved by off-target 
RGEN activity (even though their sequences are quite different from the on-
target sequences), RGENs were incubated with PCR amplicons that contain 
the potential off-target sites in vitro (Figure 19). No cleavage was detected, 
suggesting that these sites are not off-target sites. It should be noted, however, 
that exome sequencing analysis is limited by high false negative results 






















Figure 19. In vitro cleavage assay for potential off-target sequences found in 
mutant clones. The CCR5- (Upper) or C4BPB-specific (Bottom) guide-RNA 
complexed with Cas9 protein was incubated with the PCR product from wild-
type cells, which spanned the genomic region of interest. Target sites are 











Table 7. Sequence alignment to search for putative off-target sites around the 
indels identified by exome sequencing. Note that most of these putative sites 
lack the PAM sequence and that indels do not occur at expected positions (3 
base upstream of the PAM sequence), suggesting that these indels were not 




 Indels found in gene-disrupted clones and their corresponding sites in the 
reference genome are shown. The PAM sequence is shown in blue. 
** 
Note that the cut-off p-value is 10
-5
 for the BLAST search. None of these 







In this study, human genome was mutated in a targeted manner using Cas9 
endonuclease, derived from Streptococcus pyogenes. It showed that targeted 
DNA sequences mutated at a frequency of up to 75%. Although the general 
success rate of RGEN was not addressed, all 13 RGEN used were could 
induce mutations in the human genome with various efficiencies.  
ZFNs and TALENs enable targeted mutagenesis in a variety of eukaryotic 
cells and metazoans, but the mutation frequencies obtained with individual 
nuclease vary widely. Furthermore, some ZFNs and TALENs fail to show any 
genome editing activities (KIM et al. 2010; REYON et al. 2012). However, it is 
technically challenging and time-consuming to make custom nucleases. In this 
manner, RGENs have a merit compared to ZFNs or TALENs. RGENs can be 
more readily customized because only the RNA component needs to be 
replaced to make a new efficient rare-cutting nuclease. Very recently, RGENs 
were used to manipulate the genome in various cells (CHO et al. 2013a; CONG 
et al. 2013; DICARLO et al. 2013; DING et al. 2013; JIANG et al. 2013; JINEK 
et al. 2013; MALI et al. 2013b; REYON et al. 2012; SUNG et al. 2013) and 
organisms (CHANG et al. 2013; CHO et al. 2013c; FRIEDLAND et al. 2013; 
HWANG et al. 2013; LI et al. 2013a; LI et al. 2013b; LI et al. 2013c; 




2013). Furthermore, with the development of technology for synthesizing 
long ribonucleotides, RGEN is a eligible candidate for customizable, ready-
to-use endonuclease.  
Applications of engineered nucleases in research, biotechnology, and 
medicine are hampered by their off-target effects. Both ZFNs and TALENs 
can induce mutations at off-target sites that are highly homologous to on-
target sites (KIM et al. 2012; MUSSOLINO et al. 2011). Too much off-target 
DNA cleavage causes cellular toxicity. Furthermore, the repair of off-target 
DSBs gives rise to unwanted chromosomal aberrations such as deletions, 
inversions, and translocations (LEE et al. 2010; LEE et al. 2012).  
Unlike ZFNS and TALENs, whose specificities of DNA are determined by 
protein-DNA interactions that are often DNA context-dependent (SANDER et 
al. 2011) and not easy to predict, RGENs recognize target sites mostly by the 
simple Watson-Crick base-pairing rules. For example, ZFNs induce off-target 
mutations at cryptic sites that cannot be predicted based on sequence 
homology alone (GABRIEL et al. 2011). However, RGENs possibly do not 
cleave off-target DNA sequences whose recognition does not follow the base-
pairing rule. Thus, it is important to address the specificity of RGENs that 
how many mismatches RGENs can tolerate to induce mutations at off-target 
sites (CHO et al. 2013b; FU et al. 2013; HSU et al. 2013; PATTANAYAK et al. 
2013).  
As determined in this study, RGENs induce off-target mutations at sites 




target sites from off-target sites that differ by only two or three bases. 
Furthermore, exome sequencing showed that no off-target mutations were 
present in four clonal populations of mutant cells. These results suggest that 
choice of a unique target site will ensure the precise and safe genome 
manipulation at a desired locus. In principle, specificity of RGENs are fixed 
in length and are greater than human genome (4
20×42 = 1.8×1013  > 
3.0×109). It is still sufficient to ensure targeting of most genes of human 
genome if considering homologous sites with two base mismatches. For 
example, there are 28 targetable sequences in CCR5 which have no 
homologous sites including two or less mismatches (Table 8). It is possible 
that the 11 RGENs induce off-target mutations at sites not examined here, 
which could be revealed by deep sequencing at other less-homologous 
candidate sites or by whole genome sequencing. In addition, in vitro selection 
of cleavage sites (PATTANAYAK et al. 2011) or the IDLV capture approach 
(GABRIEL et al. 2011) used for the identification of ZFN off-target sites may 
reveal cryptic sites cleaved by RGENs.  
Although PAM sequence of Cas9 derived from S.pyogenes essentially 
appear every eight base pairs (4×4×2-1) in genome, it possibly limits the 
choosing target sequences. This limitation may be overcome by using other 
Cas9 variants (ESVELT et al. 2013; HOU et al. 2013) or engineered Cas9. 
  Cas9 can be used for a diverse application in molecular biology as well as 




active residue, will promise for more safe genome manipulation (MALI et al. 
2013a). Using two nicking Cas9 in pair will double the specificity of Cas9-
mediated mutagenesis (CHO et al. 2013b; RAN et al. 2013). Indeed, 
inactivated Cas9 can be used as a scaffold for delivering other functional 
domains such as transcriptional activator or repressor (GILBERT et al. 2013; 
MAEDER et al. 2013; PEREZ-PINERA et al. 2013; QI et al. 2013), or 
methyltransferase (MEISTER et al. 2010) to chromosome. 
  In summary, prokaryotic Cas9 endonuclease can function in human cells 
with high efficiency and specificity. Unlike ZFNs or TALENs, the specificity 
of RGENs can be customized by replacing a synthetic RNA molecule without 
changing the protein component. Thus, RGEN technology will be a powerful 
option that will facilitate precision genome editing in biotechnology, research 














Table 8. List of unique targetable sequences in CCR5. 
 
Target Seq Position Strand mis-0 mis-1 mis-2 mis-3 
TCATCCTGATAAACTGCAAAAGG 158 + 1 0 0 24 
TCACTATGCTGCCGCCCAGTGGG 261 + 1 0 0 5 
ACAATGTGTCAACTCTTGACAGG 295 + 1 0 0 3 
TTGACAGGGCTCTATTTTATAGG 310 + 1 0 0 6 
TATTTTATAGGCTTCTTCTCTGG 322 + 1 0 0 22 
TCATCCTCCTGACAATCGATAGG 356 + 1 0 0 2 
GGTGACAAGTGTGATCACTTGGG 438 + 1 0 0 12 
TTTACCAGATCTCAAAAAGAAGG 496 + 1 0 0 14 
CATTAAAGATAGTCATCTTGGGG 584 + 1 0 0 19 
AAAGATAGTCATCTTGGGGCTGG 588 + 1 0 0 15 
ATAATTGCAGTAGCTCTAACAGG 800 + 1 0 0 10 
CAGGTTGGACCAAGCTATGCAGG 819 + 1 0 0 5 
CTGTTCTATTTTCCAGCAAGAGG 969 + 1 0 0 13 
TCAGTTTACACCCGATCCACTGG 1009 + 1 0 0 1 
CAGTTTACACCCGATCCACTGGG 1010 + 1 0 0 2 
AGTTTACACCCGATCCACTGGGG 1011 + 1 0 0 2 
CCTGCCAAAAAATCAATGTGAAG 56 - 1 0 0 29 
CCTCCTGCCTCCGCTCTACTCAC 93 - 1 0 0 40 
CCTGATAAACTGCAAAAGGCTGA 162 - 1 0 0 15 
CCTTCTGGGCTCACTATGCTGCC 251 - 1 0 0 24 
CCCAGTGGGACTTTGGAAATACA 275 - 1 0 0 15 
CCAGGAATCATCTTTACCAGATC 484 - 1 0 0 18 
CCCTACAACATTGTCCTTCTCCT 748 - 1 0 0 22 
CCTACAACATTGTCCTTCTCCTG 749 - 1 0 0 25 
CCCCATCATCTATGCCTTTGTCG 879 - 1 0 0 10 
CCAAAAGCACATTGCCAAACGCT 936 - 1 0 0 6 
CCAAACGCTTCTGCAAATGCTGT 950 - 1 0 0 13 
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 세균이나 고세균에서 발견되는 Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-asociated (CRISPR/Cas) 시스템은 
박테리오파지나 플라스미드와 같은 외부에서 도입된 유전 물질을 
절단해서 면역 작용을 하는 것으로 알려져 있다. CRISPR/Cas type II 
시스템은 3 가지로 구성된다. 효소로 작용하는 Cas9 단백질, DNA 와 
결합하는 crRNA, 그리고 이 tracrRNA 가 존재한다. Cas9 단백질은 
crRNA, tracrRNA 와 함께 복합체를 이루어 제한 효소의 활성을 
나타내는 것으로 알려져 있다. 기존의 연구를 통해, crRNA 염기 
서열 중 일부가 20 여 개의 DNA 염기 서열을 인식해 상보적으로 
결합 할 수 있으며, 이 부분의 염기서열을 조작하면 원하는 서열을 
가지는 DNA 를 자를 수 있도록 만들 수 있다는 것이 알려져 있다. 
 본 연구에서는 CRISPR/Cas 를 이용해 인간 배양 세포에서 
선택적으로 돌연변이를 일으키는데 성공하였으며, 다양한 염기 
서열에 대해서 검증하였다. 뿐만 아니라 인간 유전체에서 유사한 
염기 서열에서 비특이적인 돌연변이가 일어 나지 않는 것을 확인 
하였다. RGEN 의 경우 손 쉽게 많은 유전자 가위를 만들 수 있고 
적용할 수 있기 때문에 과학 연구, 바이오 산업 및 치료제 개발과 
같은 의학 분야에 크게 기여 할 것이다.  
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